KRK Krka, d. d.
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives. In addition, the company offers animal health products, including antiparasitics, antimicrobials, and other products. Further, it provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Krka, d. d. (WSE: KRK)
›
Krka, d. d. (WSE: KRK) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 13,307 employees.
The shares were at 1116.00 PLN on 19 November 2026, up 25.4% over 52 weeks. Its 52-week range is 810.00 PLN to 1200.00 PLN: the price is 7.0% below the high and 37.8% above the low.
At a market capitalisation of 33.79B PLN, it trades at 19.1 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 27% for KRK. It pays a dividend yielding 3.55% (it pays out 60% of its earnings), against a median of 1.88% among the dividend payers in that peer group.
Krka, d. d. reports return on equity of 17.1%, an operating margin of 25.4% and revenue up 11.4% year over year.
It holds more cash than debt, a net cash position of 563.99M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. The next earnings report is expected on 11 March 2027.